|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Current portion of marketable securities | ||||||||||||||||||||
| Accounts receivable, net of allowance for doubtful accounts of $2.9 and $3.0, respectively | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts receivable, net of allowance for doubtful accounts of $2.9 and $3.0, respectively | ||||||||||||||||||||
| Due from anti-CD20 therapeutic programs | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Operating lease assets | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Investments and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Current portion of notes payable | ||||||||||||||||||||
| Current portion of term loan | ||||||||||||||||||||
| Taxes payable | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expense and other | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Notes payable and term loan | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Long-term operating lease liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Biogen Inc. shareholders’ equity: | ||||||||||||||||||||
| Preferred stock, par value $0.001 per share | ||||||||||||||||||||
| Common stock, par value $0.0005 per share | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock, at cost | ||||||||||||||||||||
| Total Biogen Inc. shareholders’ equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity |
Loading...
